一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Molecular Pharmaceutics >>article
Molecular Pharmaceutics

Molecular Pharmaceutics

IF: 4.5
Download PDF

Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery

Published:27 June 2022 DOI: 10.1021/acs.molpharmaceut.2c00292 PMID: 35759355
Daniel Porat, Oleg Dukhno, Ella Vainer, Sandra Cviji? and Arik Dahan*, 

Abstract

Gastrointestinal anatomical/physiological changes after bariatric surgery influence variables affecting the fate of drugs after ingestion, and medication management of these patients requires a thorough and complex mechanistic analysis. The aim of this research was to study whether loratadine/desloratadine antiallergic treatment of bariatric patients is at risk of being ineffective due to impaired solubility/dissolution. The pH-dependent solubility of loratadine/desloratadine was studied in vitro, as well as ex vivo, in gastric content aspirated from patients before versus after bariatric surgery. Then, a biorelevant dissolution method was developed to simulate the gastric conditions after sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB), accounting for key variables (intragastric volume, pH, and contractility), and the dissolution of loratadine/desloratadine was studied pre- versus post-surgery. Dissolution was also studied after tablet crushing or syrup ingestion, as these actions are recommended after bariatric surgery. Finally, these experimental data were implemented in a newly developed physiologically based pharmacokinetic (PBPK) model to simulate loratadine/desloratadine PK profiles pre- versus post-surgery. For both drugs, pH-dependent solubility was demonstrated, with decreased solubility at higher pH; over the pH range 1–7, loratadine solubility decreased ~2000-fold, and desloratadine decreased ~120-fold. Ex vivo solubility in aspirated human gastric fluid pre- versus post-surgery was in good agreement with these in vitro results and revealed that while desloratadine solubility still allows complete dissolution post-surgery, loratadine solubility post-surgery is much lower than the threshold required for the complete dissolution of the drug dose. Indeed, severely hampered loratadine dissolution was revealed, dropping from 100% pre-surgery to only 3 and 1% post-SG and post-OAGB, respectively. Tablet crushing did not increase loratadine dissolution in any post-bariatric condition, nor did loratadine syrup in post-OAGB (pH 7) media, while in post-laparoscopic SG conditions (pH 5), the syrup provided partial improvement of up to 40% dissolution. Desloratadine exhibited quick and complete dissolution across all pre-/post-surgery conditions. PBPK simulations revealed pronounced impaired absorption of loratadine post-surgery, with 84–88% decreased Cmax, 28–36% decreased Fa, and 24–31% decreased overall bioavailability, depending on the type of bariatric procedure. Desloratadine absorption remained unchanged post-surgery. We propose that desloratadine should be preferred over loratadine in bariatric patients, and as loratadine is an over-the-counter medication, antiallergic therapy after bariatric surgery requires special attention by patients and clinicians alike. This mechanistic approach that reveals potential post-surgery complexity, and at the same time provides adequate substitutions, may contribute to better pharmacotherapy and overall patient care after bariatric surgery.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Loratadine 79794-75-5 C22H23ClN2O2 892 suppliers $7.00-$112397.00
Desloratadine 100643-71-8 C19H19ClN2 748 suppliers $5.00-$1375.00

Similar articles

IF:0

Brain histamine H1 receptor occupancy measured by PET after oral administration of desloratadine and loratadine

Proceedings for Annual Meeting of The Japanese Pharmacological Society Tadaho Nakamura,?K. Hiraoka,etc Published: 1 January 2019
IF:0

Assessing patient satisfaction with desloratadine after conversion from loratadine, fexofenadine, or cetirizine.

Managed care interface Daniel Glass, Anne Harper,etc Published: 1 February 2004
IF:3.2

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Kidney Diseases Xiaoxiao Tang, Fei Liu,etc Published: 10 November 2023
富顺县| 科尔| 敦煌市| 景宁| 织金县| 青岛市| 汽车| 新密市| 石泉县| 桐城市| 商丘市| 府谷县| 庆城县| 肇东市| 永泰县| 来安县| 嘉善县| 乡宁县| 双鸭山市| 德清县| 茌平县| 屏南县| 肇庆市| 三穗县| 大理市| 贵州省| 江阴市| 赣榆县| 阿克陶县| 紫云| 习水县| 越西县| 胶南市| 昌吉市| 治县。| 枣强县| 临朐县| 北票市| 枝江市| 曲水县| 通州区|